OSLO, Norway, April 7, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”), a
clinical-stage immuno-oncology company developing novel intratumoral cancer
therapies, today announced the appointment of Ren\u00e9e Christine Amundsen as Chief
Operating Officer (COO), effective immediately. Her appointment comes at a
pivotal point as the Company continues to advance its clinical pipeline and
sharpen its operational focus for the next stage of growth.<\/p>\n
Amundsen brings more than 20 years of global leadership experience across the
pharmaceutical and life sciences industries. She has led teams and operations
through periods of scale and complexity, with a focus on translating strategy
into execution within innovation-driven healthcare companies.<\/p>\n
“We are entering an important phase for Lytix as we continue advancing our
clinical programs and building the capabilities required to deliver long-term
value,” said \u00d8ystein Rekdal, Chief Executive Officer of Lytix Biopharma. “Ren\u00e9e
brings strong execution capabilities that will enhance operational performance
and support the company’s continued growth.”<\/p>\n
As Chief Operating Officer, Amundsen will lead global operations, focusing on
preparing the Company for late-stage development and ensuring disciplined
execution across its clinical programs, including ruxotemitide and LTX-401,
while maintaining alignment across functions, timelines, and cost. <\/p>\n
Prior to joining Lytix, Amundsen served as Corporate Vice President at Novo
Nordisk and held senior leadership roles at Merck KGaA, where she led
large-scale commercial and operational initiatives and managed full P&L
responsibility across multiple markets. <\/p>\n
“I’m very pleased to be joining Lytix at such a meaningful point in its
development,” said Amundsen. “The company has built a strong foundation, and I
look forward to working with the team to support continued clinical progress and
ensure we are well positioned for the opportunities ahead.”<\/p>\n
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma’s lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.<\/p>\n
For more information, visit www.lytixbiopharma.com<\/p>\n","protected":false},"excerpt":{"rendered":"OSLO, Norway, April 7, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”), aclinical-stage immuno-oncology company developing novel…\n","protected":false},"author":2,"featured_media":52867,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[85],"tags":[31683,31684,31685,157,156,2255],"class_list":["post-57459","post","type-post","status-publish","format-standard","has-post-thumbnail","category-oslo","tag-moichc","tag-moichc20","tag-moichc2010","tag-norway","tag-oslo","tag-regulatory"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116369129752255600","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/57459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=57459"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/57459\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/52867"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=57459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=57459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=57459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}